Ali Isra, Alfarouk Khalid O, Reshkin Stephan J, Ibrahim Muntaser E
Institute of Endemic Diseases, University of Khartoum, Khartoum. Sudan.
Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari. Italy.
Anticancer Agents Med Chem. 2017;17(12):1617-1623. doi: 10.2174/1871520617666170213111951.
Cancer cells do create hostile microenvironment (deprivation of nutrients, accumulation of acidity, anoxic habitat). Those cells are not only adapted to this sanctuary environment, blunting of immunity but also, grow, migrate to the distal area (metastasis) and communicate with each other in a unique population structure and organization too (clonal expansion). The adaptation requirements push those types of adaptable cells (cancer cells) to be primitive cells. The prevailing pharmacological approach in treating cancer is developing a chemotherapeutic agent that acts on rapidly proliferating cells that are stuck with normally growing epithelium and bone marrow too. The latter approach has been drafted to work on cellular target under the term of "targeted therapy" believing that each target represents Achilles Heels of cancer. In this article, we try to introduce a new concept of cancer pharmacology, by offering new off-label use of Doxycycline, which is characterized by selective toxicity, as potential anticancer agents. This notion is relying on the absence of taxonomic barriers.
癌细胞确实会营造恶劣的微环境（营养物质匮乏、酸性物质积聚、缺氧环境）。这些细胞不仅适应这种庇护性环境，削弱免疫力，而且还会生长、迁移至远端区域（转移），并以独特的群体结构和组织方式相互交流（克隆扩增）。适应需求促使这些具有适应性的细胞类型（癌细胞）成为原始细胞。治疗癌症的主流药理学方法是研发一种化学治疗药物，该药物作用于快速增殖的细胞，而这些细胞也会影响正常生长的上皮组织和骨髓。后一种方法被拟定为在“靶向治疗”这一术语下作用于细胞靶点，认为每个靶点都是癌症的致命弱点。在本文中，我们试图引入一种癌症药理学的新概念，即提供强力霉素新的非标签用途，其具有选择性毒性，可作为潜在的抗癌药物。这一概念基于不存在分类学障碍。
